In addition, higher level of exosomal HLA-G was coupled to the presence of stem cell-like circulating tumor cells and the resulting disease progression and poor prognosis, hinting that modalities targeting exosome inhibition might serve as amplifiers of existing neoadjuvant chemotherapy to benefit breast cancer patients [142]. This evidence concerns the gene HLA-G and breast carcinoma.